Information  X 
Enter a valid email address

Evgen Pharma PLC (EVG)

  Print      Mail a friend

Tuesday 21 May, 2019

Evgen Pharma PLC

Share Option Exercise and Issue of Equity

RNS Number : 6039Z
Evgen Pharma PLC
21 May 2019

For immediate release                                                                        


Evgen Pharma plc


("Evgen" or "the Company")


Share option exercise and issue of equity



Evgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that it has received notice to exercise options over 321,600  ordinary shares in the Company.

Options over 321,600 shares were exercised pursuant to grants under individual option agreements with an exercise price of 0.875p per share. Accordingly, the Company has issued and allotted 321,600 new ordinary shares of 0.25 pence each ("New Ordinary Shares").  The New Ordinary Shares rank pari passu with the Company's existing issued ordinary shares.  Application has been made to admit the New Ordinary Shares to trading on AIM and dealings in these shares are expected to commence at 8.00 a.m. on 24 May 2019.  

There are no shares held in treasury, therefore following the admission of the New Ordinary Shares the total number of voting rights in the Company will be 132,646,263. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest under the Disclosure and Transparency Rules.




Evgen Pharma plc

Dr Stephen Franklin, CEO

Richard Moulson, CFO


c/o +44 (0) 20 7466 5000


Geoff Nash, Teddy Whiley (Corporate Finance)

Alice Lane, Manasa Patil (ECM)

+44 (0) 20 7220 0500

WG Partners LLP

Nigel Barnes, Claes Spång

+44 (0) 20 3705 9330


Mark Court, Sophie Wills, Tilly Abraham

[email protected]


+44 (0) 20 7466 5000

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit:

For research on the Company, please visit:




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t